INDICATIONS
The PCR regimen ( Table 1 ) has been studied as initial therapy for chronic lymphocytic leukemia (CLL), 1-6 small lymphocytic lymphoma, 2 Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma, 7, 8 and low-grade B-cell lymphomas. 9 Current guidelines do not list the PCR regimen as one of the regimens for treatment of Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma. 10 It is listed as one of the recommended regimens for first-line treatment of CLL in patients who are less than 65 years old without comorbidities. 11
DRUG PREPARATION
Follow institutional policies for preparation of hazardous medications when preparing pentostatin, cyclophosphamide, and rituximab. 
SUPPORTIVE CARE
A. Acute and Delayed Emesis Prophylaxis: The PCR regimen is predicted to cause acute emesis in 30% to 90% of patients. [16] [17] [18] [19] The studies reviewed reported mild (grade 1 or 2) nausea in 25% to 31% of patients 7 ; moderate to severe (grade 3 or 4) nausea or vomiting was reported in 2% to 3% of patients, respectively. 1, 5, 9 Prophylactic antiemetic therapy with a serotonin antagonist is recommended [16] [17] [18] [19] but may not be required in all patients.
One group suggests addition of a neurokinin (NK 1 ) antagonist may be appropriate in some patients. 16 One of the following regimens given 30 minutes prior to therapy is recommended: 1. Ondansetron 8 mg to 16 mg orally (PO), ±dexamethasone 12 mg PO, given 30 minutes before PCR. 2. Granisetron 1 mg to 2 mg PO, ±dexamethasone 12 mg PO, given 30 minutes before PCR. 3. Dolasetron 100 mg orally, ±dexamethasone 12 mg PO, given 30 minutes before PCR. 4. Palonosetron 0.25 mg IV and dexamethasone 12 mg PO, given 30 minutes before PCR on day 1 only. The antiemetic therapy should continue for at least 3 days. A meta-analysis of several trials of serotonin antagonists recommends against prolonged (greater than 24 hours) use of these agents, making a steroid or steroid and dopamine antagonist combination most appropriate for follow-up therapy. 20 One of the following regimens is recommended: sone to 20 mg), given 1 to 2 hours before chemotherapy.
The onset of cyclophosphamide-induced emesis is often delayed for up to 12 hours after drug administration and may persist for up to 120 hours. 21, 22 Although not well documented in the literature, some clinicians divide the daily antiemetic dose into 2 doses on days when cyclophosphamide is administered.
Patients who experience significant nausea or vomiting with one of these regimens should receive an agent from a different pharmacologic category. [16] [17] [18] [19] There is no evidence that substituting granisetron for ondansetron in subsequent treatment cycles, or increasing the dose, even to very high doses, is effective. This approach is not recommended. [23] [24] [25] [26] [27] B. Breakthrough Nausea and Vomiting [16] [17] [18] [19] : Patients should receive a prescription for an antiemetic to treat breakthrough nausea. One of the following regimens is recommended: 28 The risk of hemorrhagic cystitis increases with higher total doses of cyclophosphamide and may be further increased by radiation therapy. 28 The risk of hemorrhagic cystitis still exists with oral administration, especially since hydration cannot be monitored as closely as with IV administration. Patients taking oral cyclophosphamide should be instructed to take the medication early in the day to prevent the toxic metabolite from accumulating in the bladder overnight. 29 D. Hypersensitivity Precautions: Severe, potentially fatal, infusion-related reactions to rituximab have been reported. 12, 30, 31 Symptoms include urticaria, hypotension, angioedema, hypoxia, bronchospasm, pulmonary infiltrates, acute respiratory distress syndrome, myocardial infarction, ventricular fibrillation, cardiogenic shock, and/or nonimmunoglobulin E (IgE)-mediated reactions. 30 Immediate hypersensitivity, potentially IgE-mediated, are estimated to account for 5% to 10% of the reported reactions. 30, 31 Severe reactions usually occur within the first 30 to 120 minutes of the first infusion. Approximately 80% of fatal reactions occur with the first infusion. 12 The incidence of reactions decreases, with subsequent decrease with each subsequent exposure. The rate of occurrence of infusion reactions on first exposure also varies depending on the treatment indication (12% for Waldenstrom's macroglobulinemia, 27% for rheumatoid arthritis, and 77% for non-Hodgkin lymphoma) for reasons that are unknown. 12 Premedication and treatment of these reactions with acetaminophen and diphenhydramine is recommended. Use of bronchodilators, IV saline, glucocorticoids, or epinephrine may be indicated in some patients. 12 Rapid desensitization for hypersensitivity reactions to rituximab was described by Castells et al in a series of 413 desensitizations to various antineoplastic agents in 98 patients. 31 Castells' group described the efficacy of a 3-solution, 12-step, rapid desensitization protocol for cancer patients who experienced hypersensitivity reactions to their first-line chemotherapy agent. 32 E. Hematopoietic Growth Factors: Accepted practice guidelines and pharmaco economic analysis suggest that an antineoplastic regimen have a greater than 20% incidence of febrile neutropenia before prophylactic use of colony stimulating factors (CSFs) is warranted. For regimens with an incidence of febrile neutropenia between 10% and 20%, use of CSFs should be considered. For regimens with an incidence of febrile neutropenia less than 10%, routine prophylactic use of CSFs is not recommended. 33, 34 Since febrile neutropenia was reported in 6% of patients in the trials of PCR 5 , prophylactic use of CSFs is not recommended. Grade 3 or 4 neutropenia was reported in 20% to 53% of patients. 1, 5, 7 CSFs should be considered if a patient experiences febrile neutropenia or grade 4 neutropenia in a prior cycle of PCR.
MAJOR TOXICITIES
Most of the toxicities listed below are presented according to their degree of severity. Higher grades represent more severe toxicities. Although there are several grading systems for cancer chemotherapy toxicities, all are similar. One of the frequently used systems is the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (http://evs. nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_ QuickReference_8.5x11.pdf). Oncologists generally do not adjust doses or change therapy for grade 1 or 2 toxicities, but make, or consider, dosage reductions or therapy changes for grade 3 or 4 toxicities. Incidence values are rounded to the nearest whole percent unless incidence was less than or equal to 0.5%. A. Cardiovascular: Dehydration (grade 3) 6%. 5 B. Central Nervous System: Disturbances of consciousness (grade 3 or 4) 8%, 8 dizziness (grade 3) 0.4%. 9 C. Constitutional: Asthenia (grade 3) 6% 5 ; chills (grade 1 or 2) 18% 5 ; fatigue (grade 3) 7%, 9 (grade 4) 1% 9 ; fever (grade 1 or 2) 29%, 5 (grade 3 or 4) 6%. 5 D. Dermatologic: Alopecia (grade 3) 2%. 5 E. Gastrointestinal: Constipation (grade 3) 1% 9 ; diarrhea (grade 3) 0.2% 9 ; nausea (grade 1 or 2) 50%, 7 (grade 3) 2% to 3% 1,5 ; nausea or vomiting (grade 3) 3% 9 ; vomiting (grade 1 or 2) 25%, 7 (grade 3) 2%. 5 F. Hematologic: Anemia (grade 1 or 2) 31%, 7 (grade 3) 3%, 5 (grade 3 or 4) 9% to 25%, 1, 7, 8 (grade 4) 1% 5 ; febrile neutropenia (grade 3 or 4) 6% 5 ; leukopenia (grade 1 or 2) 56%, 7 (grade 3) 13%, 5 (grade 3 or 4), 25% to 38%, 7,8 (grade 4) 3% 5 ; neutropenia (grade 1 or 2) 29%, 5 (grade 3 or 4) 33% to 53%, 1,5,7 (grade 4) 37% 5 ; thrombocytopenia (grade 3) 4%, 5 (grade 3 or 4) 16% to 19%, 1,7 (grade 4) 1%. 5 G. Hypersensitivity: (grade 3) 4%. 5 H. Infections: Catheter-related (grade 1 or 2) 6% 7 ; pneumonia (grade 1 or 2) 3%, 5 (grade 3) 1%, 5 (grade 3 or 4) 1% to 25% 1, 5, 7 ; septicemia (grade
